|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003872,
umls-concept:C0003873,
umls-concept:C0005516,
umls-concept:C0034866,
umls-concept:C0035171,
umls-concept:C0038013,
umls-concept:C0393009,
umls-concept:C1519941,
umls-concept:C1555306,
umls-concept:C1749467,
umls-concept:C1883709,
umls-concept:C1948033,
umls-concept:C2349179
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-8-12
|
|
pubmed:abstractText |
At OMERACT 8 a framework for levels of evidence was proposed for the validation of biomarkers as surrogate outcome measures. We aimed to adapt this scheme in order to apply it in the setting of soluble biomarkers proposed to replace the measurement of damage endpoints in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We also aimed to generate consensus on minimum standards for the design of longitudinal studies aimed at validating biomarkers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
pubmed-author:AletahaDanielD,
pubmed-author:BathonJoan MJM,
pubmed-author:BoersMaartenM,
pubmed-author:BykerkVivien PVP,
pubmed-author:ChristensenRobinR,
pubmed-author:El-GabalawyHaniH,
pubmed-author:FitzgeraldOliverO,
pubmed-author:GarneroPatrickP,
pubmed-author:GeusensPietP,
pubmed-author:GladmanDafna DDD,
pubmed-author:InmanRobert DRD,
pubmed-author:KrausVirginia ByersVB,
pubmed-author:KvienTore KTK,
pubmed-author:LandewéRobertR,
pubmed-author:MaksymowychWalter PWP,
pubmed-author:MeasePhilip JPJ,
pubmed-author:OstergaardMikkelM,
pubmed-author:RitchlinChristopher JCJ,
pubmed-author:SyversenSilje WSW,
pubmed-author:TakPaul-PeterPP,
pubmed-author:TaylorWilliam JWJ,
pubmed-author:WellsGeorge AGA,
pubmed-author:van der HeijdeDésiréeD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1792-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19671814-Arthritis,
pubmed-meshheading:19671814-Arthritis, Psoriatic,
pubmed-meshheading:19671814-Arthritis, Rheumatoid,
pubmed-meshheading:19671814-Biological Markers,
pubmed-meshheading:19671814-Evidence-Based Medicine,
pubmed-meshheading:19671814-Humans,
pubmed-meshheading:19671814-Joints,
pubmed-meshheading:19671814-Longitudinal Studies,
pubmed-meshheading:19671814-Predictive Value of Tests,
pubmed-meshheading:19671814-Reproducibility of Results,
pubmed-meshheading:19671814-Spondylitis, Ankylosing
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
|
|
pubmed:affiliation |
Heritage Medical Research Building, University of Alberta, Edmonton, Alberta, Canada. walter.maksymowych@ualberta.ca
|
|
pubmed:publicationType |
Journal Article,
Consensus Development Conference
|
